Search Medical Condition
Please enter condition
Please choose location from dropdown

Vizille, France Clinical Trials

A listing of Vizille, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (364) clinical trials

The Efficacy of Cobitolimod in Patients With Moderate to Severe Active Ulcerative Colitis

This is a Phase 2b study in patients with moderate to severe active ulcerative colitis. Patients will either receive cobitolimod dose A, B or C at two occasions or dose B or placebo at four occasions. To ensure blindness patients receiving active treatment at two occasions will receive placebo at ...

Phase

8.03 miles

Learn More »

Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients

This is a double-blind, randomized-withdrawal, placebo-controlled study in kidney transplant patients with AMR to evaluate the efficacy and safety of human plasma-derived C1-esterase inhibitor as add-on to standard of care (IVIG).

Phase

8.03 miles

Learn More »

Study of BCX7353 as a Treatment for Attacks of Hereditary Angioedema

This 3-part study will evaluate the efficacy and safety of an oral kallikrein inhibitor, BCX7353, in the treatment angioedema attacks in subjects with Type I or II hereditary angioedema (HAE). In each study part, subjects will treat 3 attacks with BCX7353 (2 attacks) or placebo (1 attack), in a randomly ...

Phase

8.03 miles

Learn More »

A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma

This is a Phase III, multicenter, open-label, randomized study designed to evaluate the efficacy, safety, and pharmacokinetics of cobimetinib plus atezolizumab compared with pembrolizumab in treatment-naive participants with advanced BRAFV600 wild-type melanoma.

Phase

8.03 miles

Learn More »

Controlled Trial Evaluating Avacopan in C3 Glomerulopathy

C3 glomerulopathy (C3G) is characterized by evidence of alternative complement activation based on C3 deposition in the glomeruli. There are two forms of the disease: dense deposit disease (DDD) and C3 glomerulonephritis (C3GN). There is no approved treatment for patients with C3G. This is a randomized, double blind, placebo controlled ...

Phase

8.03 miles

Learn More »

Firazyr Patient Registry (Icatibant Outcome Survey - IOS)

The Firazyr and Cinryze patient registry is a multicenter, prospective, observational study for patients treated with Firazyr and/or Cinryze in countries where it is currently approved. The entry of participants in the Firazyr and Cinryze Registry is at the discretion of the physician and the participant and is not a ...

Phase N/A

8.03 miles

Learn More »

Effect of Adaptive Servo Ventilation (ASV) on Survival and Hospital Admissions in Heart Failure

Sleep Apnea (SA) is a disorder that causes pauses in breathing during sleep that expose the heart to oxygen deprivation. It is common in patients with heart failure (HF) where it is associated with increased risk of hospitalizations and death. It is not known however whether treating SA reduces these ...

Phase

8.03 miles

Learn More »

A French Protocol for the Treatment of Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents

A still major question in the field of acute lymphoblastic leukemia (ALL) in children - an extremely heterogeneous disease though curable in 80-90% of children and 70-80% of the adolescents - is the optimal use of L-asparaginase (ASNase). It is known that administering ASNase results in the depletion of asparagine ...

Phase

8.03 miles

Learn More »

Evaluation of APAP With SensAwake in OSA and Insomnia Patients

Patients with OSA and Insomnia will be enrolled into this randomized study to receive treatment with APAP with and without SensAwake. Baseline data will be collected for one week prior to CPAP initiation, followed by two treatment periods on each study arm of four weeks each.

Phase N/A

8.03 miles

Learn More »

Study of the Efficacy and Safety of Secukinumab in Participants With Active Psoriatic Arthritis With Axial Skeleton Involvement

The purpose of this study is to demonstrate the efficacy and safety of secukinumab 150 mg or 300 mg in the management of axial manifestations in PsA patients who have failed to respond to at least 2 non-steroidal anti-inflammatory drugs (NSAIDs) over a 4-week period, according to assessment of spondyloarthritis ...

Phase

8.03 miles

Learn More »